Compare MWA & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWA | TLX |
|---|---|---|
| Founded | 1857 | 2015 |
| Country | United States | Australia |
| Employees | 3500 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | 2006 | 2024 |
| Metric | MWA | TLX |
|---|---|---|
| Price | $25.27 | $12.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $30.50 | $21.13 |
| AVG Volume (30 Days) | ★ 1.0M | 85.6K |
| Earning Date | 05-05-2026 | 08-19-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ 64.86 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $1,429,700,000.00 | N/A |
| Revenue This Year | $4.78 | N/A |
| Revenue Next Year | $4.27 | N/A |
| P/E Ratio | ★ $23.42 | $150.33 |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $22.74 | $6.28 |
| 52 Week High | $31.00 | $12.60 |
| Indicator | MWA | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 66.07 |
| Support Level | $25.01 | $10.01 |
| Resistance Level | $25.89 | N/A |
| Average True Range (ATR) | 0.68 | 0.19 |
| MACD | -0.12 | 0.13 |
| Stochastic Oscillator | 16.03 | 95.57 |
Mueller Water Products Inc is a U.S.-based company that manufactures and sells products and services used in the transmission, distribution, and measurement of water. The company operates in two segments: Water Flow Solutions and Water Management Solutions. The Water Flow Solutions segment, which derives maximum revenue for the company, includes products like iron gate valves, specialty valves, and service brass products. Water Management Solutions' portfolio includes fire hydrants, repair and installation, natural gas, metering, leak detection, and pressure management and control products and solutions. Geographically, the company derives a majority of its revenue from the United States and the rest from Canada and other international locations.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.